Roche's Tamiflu follow-up Xofluza scores in flu-spreading study by Kyle Blankenship Tuesday, September 3, 2019 With Tamiflu sales crumbling, Roche has pivoted to next-gen flu med Xofluza as a successor. Strong preventative data could help get the job done.
Sanofi grabs OTC rights to Roche's Tamiflu by Angus Liu Tuesday, July 23, 2019 Roche has licensed Tamiflu to Sanofi, not in its current prescription status, but potential over-the-counter rights in the U.S.
Roche's Xofluza scores win in flu prevention trial by Kyle Blankenship Wednesday, June 5, 2019 With sales of Roche’s Tamiflu cratering, the company is anxiously monitoring successor Xofluza’s chances. New trial data provided a glimmer of hope.
Will mutant strains hurt prospects for Roche's Xofluza? by Carly Helfand Monday, February 11, 2019 Roche’s Xofluza has yet to see widespread uptake in the U.S., and new reports of resistance in Japan won’t help the drug’s case.
Roche’s Tamiflu successor, Xofluza, wins fast FDA nod by Angus Liu Thursday, October 25, 2018 Roche hopes the single-dose flu drug can squeeze out some generic competition to Tamiflu.
Can Roche's next-gen flu drug vie with Tamiflu generics? by Angus Liu Thursday, October 4, 2018 Xofluza only showed numerical reduction in time to symptom improvement compared with Tamiflu in complicated flu patients.
Roche’s novel flu drug helps people at high risk of complications by Angus Liu Tuesday, July 17, 2018 A phase 3 trial of Roche’s possible Tamiflu replacement in people at high risk of complications from the flu is meeting its goals.
Shionogi’s Roche-partnered flu drug Xofluza approved in Japan by Angus Liu Wednesday, February 28, 2018 Shionogi's Roche-partnered Xofluza, a one-time, single-dose regimen, probably won't win U.S. approval till next winter.
Genentech lobbyist's life and death makes pharma waves by Eric Sagonowsky Wednesday, February 15, 2017 A Genentech lobbyist who generated enormous sales for the company allegedly kept millions in consulting payments to himself.
With FDA generic nod, Roche's Tamiflu hits the exclusivity wall by Tracy Staton Thursday, August 4, 2016 When the first Tamiflu copy won FDA approval Thursday, it put a big chunk of Roche's brand sales at risk--and it’s another sign of the Swiss drugmaker’s evolution.
